Data Note: Donor Funding for the Current Ebola Response in the DRC

Published: Dec 19, 2019

Key Points

  • The ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) has required increasing amounts of external support from donors (for more information on the outbreak, see KFF’s explainer). Yet there has been limited information about donor funding to date and a lack of a centralized reporting mechanism for tracking funding.
  • This analysis provides an updated overview of donor funding for the DRC Ebola response by source. Highlights include:
    • We estimate that from August 2018, when the outbreak began, through early December 2019, approximately $734 million was provided by donors to address Ebola in the DRC.
    • More than half (57.8%) was provided by donor governments bilaterally, including the U.S., with a large share (40.1%) provided by multilateral and international organizations and a small proportion (2.2%) provided by non-profits, such as private foundations.
    • The U.S. provided the largest amount of support ($252 million), followed by the World Bank ($170 million), the United Kingdom ($78 million), the World Health Organization (WHO) Contingency Fund for Emergencies ($73 million), and the European Union ($52 million).
    • About half of funding (49%), including about a fifth of U.S. funding, was provided in direct support of the official DRC response plans, which guide national response strategy and enumerate resource needs. This could have implications for the coordination of donor efforts and whether funding is being directed to the most critical or pressing activities.
    • There is also considerable uncertainty about the future of U.S. support since it is unclear how much funding remains available for use in the response, whether the current administration will request additional funds, and whether Congress will provide such funding.

Donor Funding for the DRC Response

Based on analysis of publicly available information, we estimate that donors provided approximately $734 million in overall financial support for the DRC Ebola response from August 2018, when the outbreak began, through early December 2019 (see Table 1). We attributed funding to donor governments for Ebola when designated for this purpose, whether provided bilaterally to the DRC or earmarked for Ebola but provided to a multilateral organization or instrument. We attributed funding to a multilateral organization where that multilateral organization specifically designated general funds for this purpose. Data sources are provided in Table 1.

Table 1: Donor Funding for the Current Ebola Response in the DRC(Aug. 2018 – Dec. 11, 2019)
DonorEstimated Funding(in US$ millions)Data Source
TOTAL733.8 
Donor Governments424.0
     Australia0.4DRC/Partners SRP 3
     Canada2.2DRC/Partners SRP 3; WHO
     China3.5WHO
     Denmark4.8OCHA
     European Union52.4European Union
     France1.0OCHA
     Germany8.9WHO
     Ireland3.4OCHA; WHO
     Italy0.9   OCHA
     Japan5.1OCHA
     Luxembourg0.6WHO
     Norway3.5OCHA
     South Korea1.0WHO
     Sweden4.2WHO
     Switzerland1.4OCHA
     United Kingdom78.4U.K.; WHO
     United States252.4USAID; WHO
          Centers for Disease Control and Prevention (CDC)0.5WHO
          U.S. Agency for International Development (USAID)251.9USAID
               -Office of Foreign Disaster Assistance (OFDA)203.0USAID
               -Food for Peace (FFP)37.0USAID
               -Bureau for Global Health (GH) 12.0USAID
Multilateral and International Organizations294.0
     African Development Bank1.0WHO
     Gavi, the Vaccine Alliance26.5Gavi; WHO
     UNICEF0.3DRC/Partners SRP 2
     U.N. Central Emergency Response Fund (CERF)12.6U.N. CERF
     U.N. OCHA/DRC Humanitarian Fund10.0Humanitarian Fund
     WHO Contingency Fund for Emergencies (CFE)73.1WHO/CFE
     World Bank170.0World Bank; WHO
          Pandemic Emergency Financing Facility50.0World Bank; WHO
          International Development Association120.0World Bank; WHO
     World Food Programme (WFP)0.5DRC/Partners SRP 3
Non-Profits and Others15.9
     Gates Foundation6.0WHO
     Paul Allen Foundation0.7*WHO; KFF personal communication
     Susan T. Buffett Foundation5.0WHO
     Wellcome Trust4.2WHO
NOTES: Based on publicly-available information as of Dec. 11, 2019. * Reflects funding through Oct. 2019. May not sum to subtotal/total due to rounding. Does not include funding provided by the Democratic Republic of the Congo (DRC) government itself. OCHA amounts include commitments and paid contributions, not pledges and in-kind contributions. U.N.: United Nations. UNICEF: U.N. Children’s Fund. OCHA: Office for the Coordination of Humanitarian Affairs.

More than half (57.8%) of this funding was provided by donor governments bilaterally, including the U.S., with large share (40.1%) provided by multilateral and international organizations, such as the World Bank, and a small proportion (2.2%) provided by non-profits, such as private foundations.

The U.S. government was the largest donor, having provided $252.4 million for activities within the DRC (see Figure 1 and Box 1), followed by the World Bank ($170 million), the United Kingdom ($78.4 million), the WHO Contingency Fund for Emergencies ($73.1 million), and the European Union ($52.4 million).

Figure 1: Top 10 Donors to the Current Ebola Response in the DRC (Aug. 2018 – Dec. 11, 2019)

Box 1: Key Sources of U.S. Funding for the DRC Ebola Response

U.S. Agency for International Development (USAID)All of the USAID response funds to date have been drawn from unspent FY 2015 emergency Ebola supplemental appropriations, originally provided by Congress in December 2015. These funds, from USAID’s International Disaster Assistance (IDA) account, were designated for “assistance for countries affected by, or at risk of being affected by,” Ebola.Centers for Disease Control and Prevention (CDC)Although CDC has yet to publicly announce the amount of funding it has provided for the outbreak response in the DRC over the past year ($0.5 million is reported by WHO as having been contributed by the CDC), its Ebola response funds from Aug. 1, 2018, through Sept. 30, 2019, have been drawn from unspent FY 2015 emergency Ebola supplemental appropriations designated for Ebola international preparedness and response; according to communication with the agency, this funding was expected to be exhausted by the end of FY 2019, when it was due to expire. In recent months, Congress has stated that CDC may use existing funds in the Infectious Diseases Rapid Response Reserve Fund, which was established in FY 2019 with $50 million and could have additional funds added in FY 2020, for CDC Ebola response.

Funding for National Response Plans

The DRC government, U.N. agencies such as WHO, and other partners prepared four DRC national Strategic Response Plans (“the plans”) to guide and enumerate resource needs for the Ebola response (see Table 2). We found that about half (49%, $361 million) of donor funding for the response – including about a fifth (19%, $47.9 million) of U.S. funding – was identified as directly supporting the national plans.

Table 2: Funding Requested for the DRC Ebola Response Under National Plans(Aug. 2018 – Dec. 2019)
PeriodFunding Requested(in U.S. $ millions)Plan
Aug. – Oct. 201843.8Strategic Response Plan 1
Nov. 2018 – Jan. 201961.3Strategic Response Plan 2
Feb. – July 2019147.9Strategic Response Plan 3
July – Dec. 2019287.6Strategic Response Plan 4
NOTES: Reflects support for public health response activities; the current plan is complemented by a broader strategy that addresses additional activities related to the response. DRC: Democratic Republic of the Congo.

Donors met the funding requests in the first two plans and mostly met that of the third plan. As of early December, they have provided at least $148.3 million (via WHO) toward the fourth plan, which requests $287.6 million for public health response activities from July through December 2019.

Authorities in the DRC have also requested an additional $225.6 million for July through December 2019 under a broader strategy that includes other activities, such as economic development, to address social conditions that drive the outbreak. In support of this broader strategy, some donors have pledged more funding. The World Bank, for example, pledged up to an additional $300 million ($70 million of which has already been provided), and the United Kingdom pledged up to an additional $62.6 million, or £50 million ($9.7 million, or £8 million, of this funding has already been provided for preparedness efforts in neighboring countries, and $23.8 million of this funding has already been provided to WHO). More recently, the European Union has pledged an additional $54.7 million (€50 million) in support of the broader response.

Key Issues for the U.S. and Other Stakeholders

Maintaining a robust response to Ebola in the DRC over the next several months, and maybe even longer, will require additional donor funding. As such, there are several issues for the U.S. and other donors to consider:

  • Overall, information on donor financing is limited and fragmented. No systematic resource or tool for tracking contributions exists, a situation made more complex because the Ebola response is taking place in the context of a broad set of humanitarian crises with multiple multilateral and bilateral funding mechanisms contributing resources across a spectrum of activities (see KFF explainer). For the U.S. specifically, while some data are available, the full range of funding information has not been provided.
  • Coordination of donor funding outside official national response plans is unclear. With about half of donor funding for the response – including about a fifth of U.S. financial support – identifiable as directly supporting the official national response plans, it is not clear whether donor efforts are being coordinated effectively and funding provided for the most critical or pressing activities, including those identified under the official national response plans. With regard to the U.S. specifically, there is limited information about how U.S. funding and efforts are coordinated with U.N. and DRC-led efforts.
  • The status of U.S. funding going forward is uncertain. It is unclear how much funding remains available for use in the U.S. response, whether the current administration will request additional funds, and whether Congress will provide such funding. At USAID, it is unclear what funds remain in the leftover FY 2015 emergency Ebola funding being used for response activities. At CDC, all leftover FY 2015 emergency Ebola funding was to be spent out entirely by the end of FY 2019, but the agency may use funds from the emergency reserve fund for its Ebola activities in FY 2020 (see Box 1).

Global Health Funding in the FY 2020 Conference Agreement

Published: Dec 19, 2019

The FY 2020 appropriations conference agreement, released by Congress on December 16, 2019 and passed by both the House (12/17) and the Senate (12/19), includes funding for U.S. global health programs at the State Department, the U.S. Agency for International Development (USAID), the Centers for Disease Control and Prevention (CDC), and the National Institutes of Health (NIH). The agreement still needs to be signed by the President. Key highlights are as follows (see table for additional detail):

State Department & USAID:

  • Funding for global health programs, through the Global Health Programs (GHP) account, which represents the bulk of global health assistance, totaled $9.1 billion, an increase of $255 million above the FY 2019 enacted level, and $2.7 billion above the President’s FY 2020 request.
  • Bilateral HIV funding through the President’s Emergency Plan for AIDS Relief (PEPFAR) is $4,700 million, flat compared to the FY19 enacted level, but $1,350 million above the FY20 Request ($3,350 million).
  • The bill includes $1,560 million as the U.S. contribution to the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), an increase of $210 million above the FY19 enacted level ($1,350 million) and $602 million above the FY20 Request ($958 million). The bill states that this amount is for the first installment of the sixth replenishment. In addition, the explanatory statement accompanying the bill reaffirms the U.S. share of 33% of contributions.
  • Funding for tuberculosis (TB) totals $310 million, $8 million above the FY19 enacted level, and $49 million above the FY20 Request ($261 million).
  • Funding for malaria totals $770 million, $15 million above the FY19 enacted level ($755 million), and $96 million above the FY20 Request ($674 million).
  • The bill includes $851 million for maternal and child health (MCH), an increase of $16 million above the FY19 enacted level ($835 million), and $231 million above the FY20 Request ($629 million). Specific areas under MCH include:
    • Gavi, the Vaccine Alliance funding totals $290 million, matching the FY19 enacted level, and $40 million above the FY20 Request ($250 million).
    • Polio funding through all accounts totals $61 million, $2 million above the FY19 enacted level ($59 million), and $38 million above the President’s FY 2020 Request.
    • The bill includes $139.0 million for the U.S. contribution to the United Nations Children’s Fund (UNICEF) provided through the International Organizations and Programs (IO&P) account, $1.5 million above the FY19 enacted level ($137.5 million). While the FY20 Request did not specify a funding amount for UNICEF and proposed to eliminate the IO&P account, it is possible that organizations such as UNICEF could receive funding through other accounts.
  • Funding for nutrition totals $150 million, $5 million above the FY19 enacted level ($145 million), and $71 million above the FY20 Request ($79 million).
  • Bilateral family planning and reproductive health (FP/RH) funding totals $575 million ($524 million through the GHP account and $51 million through the ESF account), matching the FY19 enacted level, and $316 million above the FY20 Request ($259 million).
  • Funding for the United Nations Population Fund (UNFPA) totals $32.5 million, matching the FY19 enacted level; the FY20 Request proposed eliminating funding for UNFPA.
  • Funding for the vulnerable children program totals $25 million, $1 million above the FY19 enacted level ($24 million); the FY20 Request proposed eliminating funding for this program.
  • Funding for neglected tropical diseases (NTDs) totals $102.5 million, matching the FY19 enacted level, and $27.5 million above the FY20 Request ($75 million).
  • Funding for global health security (GHS) totals $100 million in the bill. While this is a decrease compared to the FY19 enacted level ($138 million), $38 million of the FY19 amount was provided through a one-time transfer of unspent emergency Ebola funding. The FY20 conference agreement amount is a $10 million increase compared to the FY20 Request ($90 million).

Centers for Disease Control and Prevention (CDC): Funding for global health provided to the CDC totals $571 million, an increase of $75 million compared to the FY19 enacted level ($496 million) and $114 million above the FY20 Request ($457 million). The entire increase in CDC funding is to support global health security activities.

Fogarty International Center (FIC): Funding for the Fogarty International Center (FIC) at the National Institutes of Health (NIH) totaled $81 million, $3 million above the FY 2019 enacted level ($78 million) and $14 million above the FY20 Request.

Additional Global Health Legislation: The appropriations bill also included the “End Neglected Tropical Diseases Act” as well as the “Preventing Child Marriage in Displaced Populations Act.” Learn more about these two bills on the KFF U.S. Global Health Legislation Tracker here.

Additional Resources:

The table below compares global health funding in the FY 2020 conference agreement to the FY 2019 enacted funding amounts as outlined in the “Consolidated Appropriations Act, 2019” (P.L. 116-6; KFF summary here), the President’s FY 2020 request (KFF summary here).

Table: KFF Analysis of Global Health Funding in the FY20 Conference Agreement
Department / Agency / AreaFY19Enactedi(millions)FY20Requestii(millions)FY20Conference Agreement(millions)Difference(millions)
FY20 Conference– FY19 EnactedFY20 Conference– FY20 Request
 State & Foreign Operations (SFOPS)
HIV/AIDS$4,700.0$3,350.0$4,700.0$0(0%)$1350(40.3%)
State Department$4,370.0$3,350.0$4,370.0$0(0%)$1020(30.4%)
USAID$330.0$0.0$330.0$0(0%)$330.0(NA)
of which Microbicides$45.0$0.0$45.0$0(0%)$45.0(NA)
Global Fund$1,350.0$958.4$1,560.0$210(15.6%)$601.6(62.8%)
Tuberculosisiii$262.0
Global Health Programs (GHP) account$302.0$261.0$310.0$8(2.6%)$49(18.8%)
Economic Support Fund (ESF) accountNot specified$1.0Not specified
Malaria$755.0$674.0$770.0$15(2%)$96(14.2%)
Maternal & Child Health (MCH)ivv
GHP accountvi$835.0$619.6$851.0$16(1.9%)$231.4(37.3%)
of which Gavi$290.0$250.0$290.0$0(0%)$40(16%)
of which Poliovi$51.5$16.0$61.0$9.5(18.4%)$45(282.2%)
UNICEFvii$137.5Not specified$139.0$1.5(1.1%)
ESF accountNot specified$75.5Not specified
of which Poliovi$7.5$7.0vi
Nutritionviii$89.7
GHP account$145.0$78.5$150.0$5(3.4%)$71.5(91.1%)
ESF accountNot specified$11.2Not specified
Family Planning & Reproductive Health (FP/RH)$607.5$259.0$607.5$0(0%)$348.5(134.6%)
Bilateral FPRH$575.0$259.0$575.0$0(0%)$316(122%)
GHP account$524.0$237.0$524.0$0(0%)$287(121.1%)
ESF account$51.1$22.0$51.1$0(0%)$29.1(132%)
UNFPA$32.5$0.0$32.5$0(0%)$32.5(NA)
Vulnerable Children$24.0$0.0$25.0$1(4.2%)$25.0(NA)
Neglected Tropical Diseases (NTDs)$102.5$75.0$102.5$0(0%)$27.5(36.7%)
Global Health Security$138.0$90.0$100.0$-38(-27.5%)$10(11.1%)
GHP account$100.0$90.0$100.0$0(0%)$10(11.1%)
Ebola transfer$38.0$0.0$0.0$-38(-100%)$0.0(0%)
Emergency Reserve Fund$2.0$0.0ix
Ebola transfer$2.0$0.0$0.0$-2(-100%)$0.0(0%)
SFOPs Total (GHP account only)$8,837.5$6,343.5$9,092.5$255(2.9%)$2748.9(43.3%)
Health & Human Services (HHS)
Centers for Disease Control & Prevention (CDC) – Total Global Health$495.8$457.0$570.8$75(15.1%)$113.9(24.9%)
Global HIV/AIDS$128.4$69.5$128.4$0(0%)$58.9(84.7%)
Global Tuberculosisx$7.2$7.2$7.2$0(0%)$0(0%)
Global Immunization$226.0$206.0$226.0$0(0%)$20(9.7%)
Polio$176.0Not specified$176.0$0(0%)
Other Global Vaccines/Measles$50.0Not specified$50.0$0(0%)
Parasitic Diseases$26.0$24.5$26.0$0(0%)$1.5(6.3%)
Global Public Health Protectionxi$108.2$149.8$183.2$75(69.3%)$33.4(22.3%)
Global Disease Detection and Emergency Response$98.4Not specified$173.4$75(76.2%)
of which Global Health Security (GHS)$50.0$99.8$125.0$25.2(25.3%)
Global Public Health Capacity Development$9.8Not specified$9.8$0(0%)
National Institutes of Health (NIH) – Total Global Health$880.2$760.1Not yet known
HIV/AIDS$590.1$511.1Not yet known
Malaria$212.0$182.0Not yet known
Fogarty International Center (FIC)$78.1$67.0$80.8$2.7(3.4%)$13.8(20.5%)
Notes:
i – The FY19 Enacted includes the transfer of $40.0 million in unspent Emergency Ebola funding including: $2.0 million for the Emergency Reserve Fund and $38.0 million for “programs to accelerate the capacities of targeted countries to prevent, detect, and respond to infectious disease outbreaks.”
ii – In the FY20 Request, the administration proposed to consolidate the Development Assistance (DA), Economic Support Fund (ESF), the Assistance for Europe, Eurasia, and Central Asia (AEECA), and the Democracy Fund (DF) accounts in to one new account — the Economic Support and Development Fund (ESDF). ESF funding for the FY20 Request reflects the amounts requested by the administration for ESDF.
iii – Some tuberculosis funding is provided under the ESF account, which is not earmarked by Congress in the annual appropriations bills and determined at the agency level (e.g. in FY17, TB funding under the ESF account totaled $2.64 million).
iv – Some MCH funding is provided under the ESF account, which is not earmarked by Congress in the annual appropriations bills and determined at the agency level (e.g. in FY17, MCH funding under the ESF account totaled $56.54 million).
v – It is not possible to calculate total MCH funding in the FY20 request because UNICEF, which has historically received funding through the International Organizations and Programs (IO&P) account, was not specified in the FY20 request.
vi – The minority summary of the FY20 conference agreement states that part of the increase in MCH funding is “due to a shift of $7.5 million for polio prevention programs from the Economic Support Fund account to the Global Health Programs account.”
vii – UNICEF funding in the FY19 bill and the FY20 Conference Agreement both include an earmark of $5 million for programs addressing female genital mutilation.
viii – Some nutrition funding is provided under the ESF account, which is not earmarked by Congress in the annual appropriations bills and determined at the agency level. (e.g. in FY17, nutrition funding under the ESF account totaled $21 million).
ix – The explanatory statement accompanying the FY20 Conference Agreement states that the “agreement includes authority to reprogram $10,000,000 of Global Health Program funds to the Emergency Reserve Fund if necessary to replenish amounts used during fiscal year 2020 to respond to emerging health threats.”
x – In FY20, the administration proposed to formally transfer $7.2 million from the “HIV/AIDS, Viral Hepatitis, STI and TB Prevention” account to “Global Tuberculosis” activities under “Global Health Programs” at CDC. The FY20 conference agreement formalizes this transfer. The FY19 total has been adjusted to reflect this administrative change.
xi – In the CDC FY20 congressional justification, this funding line is titled “Global Disease Detection and Other Programs”.
Updated: December 19, 2019

10 Key Questions on Public Option Proposals

Authors: Tricia Neuman, Karen Pollitz, Jennifer Tolbert, Robin Rudowitz, and Wyatt Koma
Published: Dec 18, 2019

Several democratic presidential primary candidates and Members of Congress have proposed or endorsed a “public option” to expand health coverage and lower health care costs, giving people the choice between private insurance and a publicly-sponsored plan. The approaches of public option proposals differ from Medicare-for-all in that they expand upon, rather than replace, current sources of coverage (e.g., employer-sponsored plans, the marketplaces, Medicare, and Medicaid). Similar to Medicare-for-all, a public option could make broader use of Medicare-like provider payment rates, lowering the cost of coverage relative to private insurance. Recent polls find greater support for a public option than for Medicare-for-all.

Democratic candidates Biden, Buttigieg, Steyer, and Warren have each proposed a public option approach that aims to broaden coverage and make health care more affordable. Senator Warren describes her public option as an incremental measure before pushing for subsequent passage of separate Medicare-for-all legislation. Public option proposals vary in how many people would gain coverage, the number of people who shift from their current health plan to the public option, the potential size of the public option, the affordability of coverage, and changes in spending by the federal government and other payers. The impact on coverage and affordability would depend on factors such as eligibility criteria, the scope of covered benefits, the level of subsidies provided, and provider payment rates. See Table 1 for short descriptions of each proposal.

This issue brief presents a high-level view of key questions regarding current public option proposals supported by both presidential candidates and Members of Congress.

Background

As Congress debated the Affordable Care Act (ACA) ten years ago, some lawmakers supported a public option to address anticipated concerns about private insurer participation in new ACA marketplaces and the stability of private plan offerings, and to leverage greater competition to help lower costs and premiums in the marketplaces. The House-passed version of the ACA included a public option, offered only through the marketplace, which would cover the same benefits and be subject to the same standards as other marketplace plans. Ultimately, that provision was dropped from the final legislation when it was considered by the Senate.

Since then, some policymakers have continued to press for a public option. Congressional bills to establish a public option since 2017 have evolved and included other ACA enhancements. This year, presidential candidates have proposed public options that could be even more expansive, offering more Americans a choice between their current private-sector coverage and a public option. Some are described as a glide path or transition to Medicare-for-all.

The health insurance industry and many provider organizations have opposed a public option. Private insurers raise concerns that they would have difficulty competing on a level playing field with a public option, and ultimately would be put out of business. Hospitals and other health care providers raise concerns about the adequacy of payment rates in a public option and potential loss of revenues.

1. How would a public option differ from Medicare-for-all?

Unlike Medicare-for-all, a new public option would be offered as an option for eligible individuals rather than replacing current sources of coverage. Under most proposals, the public option would be administered by the federal government, as Medicare is today. An alternative approach would allow states to build a public option based on the Medicaid program.

Medicare-for-all proposals aim to achieve universal and cradle-to-grave coverage. In contrast, under a public option proposal, people could still be at risk for coverage lapses when life events (such as job loss or a change in income) force transitions. Some proposals try to minimize coverage gaps by providing for the automatic enrollment of the uninsured or others into the public option. The extent to which a public option would move toward universal coverage would depend in large part on how much it would increase affordability of insurance through lower payment rates to providers and increased subsidies for individuals.

2. Who would be eligible for the public option?

Eligibility for the public option varies across proposals, and some proposals would provide for auto-enrollment of certain individuals. Examples of eligibility differences include:

  • Marketplace participants only – Some proposals would offer the public option only in the marketplace; others would further limit the option to marketplace eligible individuals age 50-64.
  • Employers – Employers would also have access to the public option under some proposals. Several congressional bills would allow small employers to purchase or provide group coverage through the public option, as would the proposal by presidential candidate Buttigieg; one of these bills also opens the public option to large employers and permits employees to remain in the public option if they change jobs.
  • People who are offered employer coverage – Presidential candidates Biden, Buttigieg, Steyer, and Warren as well as a congressional proposal, known as Medicare for America, would adopt a more expansive approach that allows workers (and their dependents) who are offered job-based coverage to instead enroll in the public option and receive subsidies for their coverage. This approach differs from current law in that those with an offer of job-based coverage are generally ineligible for marketplace subsidies.1  Allowing people to get coverage through a subsidized public option, instead of their employer, could make the public option a particularly attractive alternative for low-wage workers and their families.
  • People eligible for Medicare or Medicaid – With the exception of the congressional proposal, Medicare for America, the other public option congressional proposals would not allow people eligible for the current Medicare or Medicaid programs to enroll in the public option. Medicare for America would replace Medicare and Medicaid with the new public program. Buttigieg and Warren open the public option to individuals enrolled in Medicaid, while Biden and Steyer would allow states to shift some or all of their Medicaid enrollees into the public option. In addition, Biden, Buttigieg and Steyer would automatically enroll into the public option all eligible low-income individuals living in states that have not expanded Medicaid..Warren’s proposal would enroll all children and adults with incomes below 200% of poverty who are younger than age 50 into the public option, though individuals may opt out for other coverage.2  Warren would make older adults (50-64) eligible for expanded coverage under the existing Medicare program. The Warren approach would offer an alternative to Medicaid coverage for the majority of low-income people currently eligible for Medicaid.
  • Immigrants – Most proposals would exclude undocumented immigrants from coverage. Warren would extend eligibility for marketplace subsidies to those eligible for the Deferred Action for Childhood Arrivals program, which would make them eligible for her public option, and Steyer would allow undocumented immigrants to enroll in the public option. Other proposals do not specify.

As noted above, several proposals would auto-enroll certain individuals into the public option with no premium, with an “opt out” if they prefer other coverage – an approach that would expand the size of the public program. The Medicare for America bill would auto-enroll everyone in the public option, while allowing people with access to qualified employer coverage to opt out.

3. How would benefits under a public option compare to other coverage?

Under the Biden and Buttigieg proposals and others the public option would cover essential health benefits, similar to marketplace qualified health plans (QHPs) and most employer-sponsored health plans.3  Biden’s proposal would extend the “full scope of Medicaid benefits” to enrollees with income up to 138% of poverty. Congressional proposals to create a Medicare buy-in option for older adults would give enrollees the same benefits as the current Medicare program, which differ somewhat from essential health benefits; for example, the current Medicare program does not have a limit on out-of-pocket spending.

Several proposals specify that reproductive services, including abortion, would be covered under the public option, and that the Hyde Amendment, which prohibits federal funding for abortion services in most circumstances, would be repealed.

Under Senator Warren’s proposal and the Medicare for America bill, the public option would cover a substantially broader set of benefits, including long-term services and supports (LTSS), dental benefits, and others. A public option that covers more comprehensive benefits with a broader network of providers than private plans could attract a sicker and more expensive population, which could increase the cost of the public option (and taxes required to support it) while relieving families and others of these expenses.

4. What about cost sharing and cost-sharing subsidies in the public option?

Rising deductibles and cost-sharing requirements are a growing concern for people with job-based and marketplace coverage. Over the past decade, deductibles in employer plans have risen six times faster than wages. The average deductible under silver-tier marketplace plans is $4,544 per person in 2020 (unweighted), though cost-sharing reduction (CSR) subsidies, available to people with income up to 250% of the federal poverty level (FPL), reduce silver plan deductibles for about half (52%) of marketplace enrollees.

Candidates Biden, Buttigieg, and Steyer would reduce ACA cost-sharing for those in both marketplace plans and the new public option. Their proposals would set the benchmark marketplace plan at the gold level, instead of silver, to lower deductibles and other out-of-pocket costs. Some proposals would expand eligibility for cost-sharing subsidies to those with income above 250% FPL, and up to 400% FPL in some cases.4  Proposals that let would employees elect the public option and receive subsidies instead of job-based coverage could extend cost sharing relief to some low-wage workers.

Warren takes a different approach. In addition to enhancing marketplace cost-sharing subsidies as do the other candidates, cost sharing under the public option would be even lower. Cost sharing in Warren’s public option would be set at the platinum level (which covers 90% of costs) instead of gold (which covers 80% of costs). In addition, deductibles would be eliminated for all public option enrollees, and there would be no cost sharing for enrollees with income up to 200% FPL. Co-insurance would apply for people with incomes above 200% FPL up to an out-of-pocket cap, but would phase out over time. These features would reduce out-of-pocket health care spending for many people relative to private insurance.

5. How would premiums and premium subsidies work?

How attractive the public option is to individuals will largely depend on the relative affordability of premiums in the public option. The availability and level of premium subsidies will be an important factor, particularly to individuals who are currently ineligible for marketplace subsidies due to income or because they are offered employer coverage. Other factors that could affect the premium in the public option include benefits and cost sharing, and provider payment rates. Premiums for public option enrollees could be higher (or lower) depending on the risk profile of individuals who elect coverage under the public option. If the public option experiences adverse selection, premiums could be higher than private insurance and rise over time, although in virtually all proposals, public option premiums would be capped as a percentage of income for enrollees.

Like marketplace plans, the public option premiums generally could vary by age, geography, family size, and tobacco use.

Most proposals would expand premium subsidies relative to those that are currently available to marketplace enrollees. Several would make the public option free for low-income people – those with income up to 200% FPL under Warren’s proposal, and up to 138% FPL for some or all people under proposals by Biden, Buttigieg, and Steyer. Many would also cap premium contributions for people with higher incomes. Premiums would be capped at 5% of income under Warren, 8% under Medicare for America, and 8.5% under Biden, Buttigieg, and Steyer. These caps are lower than the current 9.78% premium cap, which is only available to people with incomes up to 400% of poverty. Premiums would be eliminated over time under the Warren proposal. In addition, all of the candidate proposals and the Choose Medicare Act (Sen. Merkley/ Rep. Richmond) would enhance marketplace premium subsidies by changing the benchmark plan, on which subsidies are based, from silver level to gold level.

6. How would health care providers be affected?

The relative affordability of the public option would also depend on the level of provider payments. This is because private insurers typically pay higher prices than Medicare for covered services. For example, a Congressional Budget Office (CBO) analysis found that Medicare hospital payment rates were 47% below those of commercial insurers, on average, though with wide variation by geography and other factors.5  Medicare’s role in setting payment rates has contributed to slower growth in spending for Medicare than private insurance. Adopting Medicare rates could also reduce or eliminate the problem of surprise medical bills, as Medicare limits what providers can charge and prohibits balance billing.

However, health care providers are likely to oppose this approach, based on concerns about the adequacy of payment rates, and the impact on patient care. An ongoing question is how hospitals and other health care providers would respond to lower payment rates, and whether they would be able to achieve efficiencies without jeopardizing quality of care.

  • Use of Medicare payment rates – Several proposals would build on the Medicare provider payment system. The Warren proposal, for example, would phase down payment rates before ultimately paying 110% of Medicare rates for hospitals and Medicare rates for other providers once the Medicare-for-all program takes effect. Buttigieg would limit out-of-network payment rates for all hospitals and providers at 200% of Medicare rates, with the public option presumably paying no more than that; rural providers would receive higher payments. Some other proposals do not specify the level of provider payments under the public option, saying more generally that they would be “based on” Medicare rates..Another approach included in the Merkley/Richmond bill would allow self-funded employer plans to contract with the public option as a third party administrator (TPA). This would give employers access to the public option’s provider network and payment rates. Under this proposal, over time, the public option could move toward an all-payer-rate setting system, even while preserving private employer coverage and financing.
  • Provider participation in the public option – Proposals also vary in whether they encourage providers to participate in the public option. Under proposals by Warren and Steyer, hospitals, physicians and other health care providers who participate in the current Medicare (and Medicaid) programs would also participate in the public option. In other proposals, such as the Medicare-X Choice Act introduced by Senator Bennet, provider participation in the public option would not be linked to participation in Medicare. Others, such as Biden and Buttigieg, do not specify.Part of the appeal of the current traditional Medicare program is its broad and national provider network. If provider participation in the new public option is not tied to Medicare, this could result in a narrower provider network, which could be a concern for enrollees. Moreover, voluntary participation could undermine the government’s ability to set lower payment rates than it could if all or virtually all providers participated, as is now the case with the current Medicare program.

7. How would public option proposals affect employer-sponsored and other private coverage?

One controversial element of Medicare-for-all is that it would replace private coverage that people have today. Public option proposals would instead retain current coverage and offer an additional choice. Candidates Biden, Buttigieg, Warren and Steyer all would let people with job-based plans opt for the public option and receive subsidies for that coverage (this is also a feature of the Medicare for America bill). Warren would also offer substantially more generous benefits under the public option than most employers offer today. The relative attractiveness of the public option – e.g. due to its covered benefits or subsidies – could lead more workers to elect it over time, ultimately diminishing the role of employer coverage.

The broad availability of a public option could also lead some employers to decide to stop offering plans they sponsor today. Whether and which firms continue offering private coverage would depend on a number of factors, including how many enrollees would prefer to keep their employer plan, the average cost of covering remaining employees, and the employer’s cost of maintaining the plan relative to the cost of paying the large employer mandate penalty under the ACA. The substantial federal tax preference accorded to employer-sponsored group health benefits today could also affect decisions of firms to keep offering job-based coverage and worker decisions to participate. Unlike wages, health benefits are not subject to federal income or payroll tax.

The public option could also significantly affect non-group insurance. A public option could strengthen incentives for private insurers to compete on value and cost. A new public option could offer consumers an additional plan choice, particularly in marketplace areas served by a single insurer. On the other hand, if private insurers are unable to compete effectively, the public option could draw substantial enrollment away from them and might become the sole option in at least some areas.

8. How would public option proposals affect the current Medicare program?

All of the public option proposals would retain the current Medicare program. Although many invoke the Medicare name, such as Medicare For All Who Want It, Medicare Choice, and Medicare Part E, the new public options are intentionally structured to be separate from the current Medicare program and differ from it in many respects.

Most proposals would not allow people who are eligible for the current Medicare program to enroll in the new public option, and most leave the current program as is. Some create a firewall between the new public option and Medicare, explicitly stating that the new public option will not have any effect on premiums in the current Medicare program or finances (e.g. the Medicare Hospital Insurance Trust Fund).

Some proposals would make improvements to the current Medicare program. The Buttigieg proposal and the Merkley bill, for example, would add an out-of-pocket limit to traditional Medicare. The Higgins bill would create a new voluntary Medigap option to make cost sharing more affordable for people with Medicare. Virtually all of the proposals would address the price of prescription drugs in Medicare as they do for the public option (e.g., allow the government to negotiate lower prices). Warren’s proposal would match benefits under the current Medicare program to the public option “to the extent possible”.

In contrast to other proposals, the Warren proposal would lower the age of eligibility for Medicare to 50, but would allow people age 50-64 to go in (or out) of the Medicare program. Her proposal would automatically enroll all 50-64 year olds who are uninsured or living on incomes below 200% of poverty into the Medicare program with no premiums, deductibles or cost sharing. This approach would substantially increase the size of the current Medicare program, and could potentially affect the Medicare Hospital Insurance Trust Fund unless safeguards are put in place. At the same time, the infusion of younger adults into the current Medicare program could lead to lower per capita costs, which could result in lower Medicare premiums.

9. How would public option proposals affect Medicaid?

Proposals also differ in what happens to the Medicaid program and in how they address the coverage gap in states that have not adopted the Medicaid expansion. Many congressional proposals would retain the Medicaid program and would not permit people eligible for Medicaid to enroll in the public option; they also would not address the lack of coverage for poor adults living in states that did not expand Medicaid. In contrast, the presidential candidates’ proposals and the Medicare for America bill would have broader implications for Medicaid, and most would cover low-income adults in non-expansion states.

Candidates Biden, Buttigieg, and Steyer would auto-enroll into the public option low-income uninsured individuals living in the 14 states that did not expand Medicaid. These individuals would receive free coverage through the public option. The Buttigieg plan would allow individuals who are uninsured, have private coverage or Medicaid to opt into the public option while plans offered by Biden and Steyer would allow states to shift some or all of their Medicaid enrollees into the public option and make a maintenance of effort (MOE) payment instead, though how that MOE would work is not specified. These proposals do not specify whether the public option would cover all benefits that are currently covered by Medicaid, such as LTSS and non-emergency medical transportation, for this population.

Warren’s proposal would auto-enroll into the public option, with an opt out, a much larger group of people, including people who are currently eligible for Medicaid or in the Medicaid coverage gap. Children up to age 18 would be auto-enrolled, as would adults up to age 50 with incomes below 200% of poverty. Adults age 50-64 would be eligible for Medicare. Under this proposal, the public option and expanded Medicare program would be offered as an alternative to Medicaid and CHIP. States would also be permitted to move other Medicaid enrollees into the public option and make an MOE payment instead, thus eliminating Medicaid altogether in these states.

This proposal raises a number of important questions for the Medicaid population, particularly adults age 50-64 with long-term care needs, as well as for states. For example, while the public option would guarantee coverage vision, dental, and LTSS, these benefits would only be provided to the “greatest extent possible” under Medicare. The proposal also does not specify if low-income individuals ages 50-64 in Medicare would have access to free coverage, as would be the case for younger adults and children under the public option.

Unlike other proposals, the Medicare for America bill would explicitly eliminate the Medicaid program, moving all Medicaid enrollees into the public option. To ensure Medicaid enrollees receive the same coverage under the public option, Medicare for America would cover all benefits provided by state Medicaid programs as part of the benefit package.

One congressional bill (Schatz/Lujan) differs from the others in that it would permit states to build on the existing Medicaid infrastructure to create a Medicaid-like public option. Yet, even with this proposal, the Medicaid program would remain intact for existing Medicaid enrollees — the Medicaid buy-in would target those who are eligible for marketplace coverage, not those currently eligible for Medicaid. Although it seeks to address the coverage gap, it would do so by extending 100% federal financing for the expansion for three years for any state that newly adopts the expansion. Individuals with incomes below 138% of poverty in states that continue to refuse to adopt the expansion would remain uninsured and without an affordable coverage option.

10. What do we know about the cost of these proposals?

The Congressional Budget Office (CBO) has not estimated any of the public option bills introduced in the 116th Congress. In general, a public option can be expected to have less of an effect on federal spending and revenues than Medicare-for-all. The federal cost of a public option could be higher or lower depending on many factors, including benefits, subsidies, the number of people who enroll, and the extent to which costs shift from individuals and other payers to the public option. Federal spending could also rise due to induced demand resulting from more people with coverage, and lower cost-related barriers to care. New federal costs could be offset somewhat to the extent the public option uses lower provider payment rates. The cost of federal marketplace subsidies could also be offset to the extent that public option premiums are lower than what commercial insurers charge today, depending on the details of how subsidies are determined.

A public option could also affect costs borne by individuals, employers and states. Proposals that provide enhanced cost-sharing and premium subsidies in the public option, and make more people eligible for these subsidies, could improve affordability for millions of Americans. However, public option proposals do not go as far as Medicare-for-all proposals that eliminate premiums and cost-sharing and provide comprehensive benefits. Employers could realize savings if employees opt into the public option, subject to contribution requirements. Employers could also achieve savings if they are able to access public option provider payment rates. The fiscal impact on states would depend on the extent to which Medicaid enrollees would shift to the public option, and related MOE requirements.

Discussion

Recent polls have shown substantial support for a public option, relative to Medicare-for-all, in part because it would give individuals another “choice” rather than require all people to be covered under one program that replaces current sources of coverage. Public support for Medicare-for-all drops when people are told that it would eliminate private insurance and employer-sponsored coverage, and threaten the Medicare program. The public option is viewed as less disruptive than Medicare-for-all, even though it could replace a significant amount of private plan coverage under some proposals. In fact, support for a public option drops when people are told it could reduce payments to hospitals and doctors or lead to too much government involvement in health care.

A public option could have a modest or significant effect on health coverage and costs in the U.S., depending on how it is structured. The effect could be minimal if the public option is available to a limited subset of the population, with benefits, cost sharing and subsidies similar to marketplace coverage, and if providers can participate voluntarily with little change in their payment rates. However, a public option could have a more dramatic impact on coverage and costs if it is widely available, offers more comprehensive benefits at lower costs, extends subsidies to people now in job-based plans, and uses Medicare provider payment rates.

Ultimately, with many different proposals on the table, it is important to examine key details that could determine the impact of a public option on coverage and affordability, and the level of disruption to the current health care system.

Table 1: Public Option Proposals Introduced by Presidential Candidates
PRESIDENTIAL CANDIDATES’ PUBLIC OPTION PROPOSALS
ProposalGeneral Approach
Biden

The Biden Plan To Protect & Build On The Affordable Care Act

  • Creates a federal public option available to marketplace-eligible individuals, people with employer coverage, and low-income adults in the Medicaid coverage gap; low-income uninsured in coverage gap states automatically enrolled
  • Allows Medicaid expansion states to move expansion adults into the public option with MOE
  • Covers ACA essential health benefits; provides “full scope of Medicaid benefits” to those <138% FPL
  • Sets Gold-level plan as marketplace benchmark plan to increase premium subsidies and lower deductibles and out-of-pocket costs for all marketplace enrollees
  • Eliminates income limit on eligibility for premium tax credits and caps premium payments at 8.5% of income; no premiums <138% FPL; those with job-based coverage eligible for subsidies
  • Negotiates payments to providers; provider participation requirements not specified
Buttigieg

Medicare For All Who Want It

  • Creates a federal public option available to marketplace-eligible individuals, people with employer coverage and Medicaid; low-income uninsured in coverage gap states automatically enrolled
  • Allows employers to buy into the public option
  • Covers ACA essential health benefits
  • Sets Gold-level plan as marketplace benchmark plan to increase premium subsidies and lower deductibles and out-of-pocket costs for all marketplace enrollees
  • Eliminates income limit on eligibility for premium tax credits and caps premium payments at 8.5% of income; no premiums <138% FPL; those with job-based coverage eligible for subsidies
  • Pays rural hospitals and certain other providers higher than current Medicare rates; provider participation requirements are not specified
Steyer

Every American Has a Right to Health Care

  • Creates a federal public option available to marketplace-eligible individuals, people with employer coverage, low-income adults in the Medicaid coverage gap, and undocumented immigrants; low-income uninsured automatically enrolled in public option or Medicaid
  • Allows Medicaid expansion states to move covered adults into the public option; small employers can buy into public option
  • Sets Gold-level plan as marketplace benchmark plan to increase premium subsidies and lower deductibles and out-of-pocket costs for all marketplace enrollees
  • Caps premium payments at 8.5% of income for those above 400% FPL; no premiums <138% FPL; those with job-based coverage eligible for subsidies
  • Negotiates payments to providers; providers that participate in Medicare or Medicaid must participate in public option
Warren

My First Term Plan For Reducing Health Care Costs In America And Transitioning To Medicare For All

  • Creates a federal public option available to all children, and adults who are not otherwise eligible for Medicare; auto-enrolls all children and low-income uninsured under age 50, with opt out for other coverage allowed
  • Encourages states to move Medicaid enrollees into the public option with MOE
  • Covers essential health benefits, dental, vision, hearing, and long-term care in public option
  • Eliminates premiums and cost sharing in the public option for all children, and adults below 200% FPL. For other adults, sliding scale premiums capped at 5% of income and cost sharing scaled modestly with caps on out-of-pocket costs; no deductibles; people offered job-based coverage eligible for public option subsidies; premiums and cost sharing eliminated over time
  • Sets Gold-level plan as marketplace benchmark plan; lifts income limit for eligibility for premium subsidies and lowers cap on premium payments for all marketplace enrollees; increases eligibility for cost sharing subsidies
  • Requires Medicare providers to participate in public option; payment rates set higher than Medicare rates initially but gradually reduce to Medicare rates
  • Expands Medicare eligibility to adults 50-64; uninsured adults 50-64 are automatically enrolled in expanded Medicare with opt out for other coverage allowed and adds dental, vision, hearing and LTC to the “greatest extent possible”
CONGRESSIONAL PUBLIC OPTION PROPOSALS
ProposalGeneral Approach
Cardin

S.3, Keeping Health Insurance Affordable Act of 2019

  • Creates a federal public option available to marketplace-eligible individuals
  • Does not change marketplace subsidies
  •  Requires Medicare providers to participate in public option; Medicare payment rates used initially, with adjustments by the Secretary starting in 2023
Stabenow/ Higgins

S 470, HR 1346, Medicare at 50 Act

  • Creates a Medicare buy-in option for individuals 50 and over
  • Applies marketplace premium and cost sharing subsidies to the Medicare buy-in; cost sharing subsidies enhanced for others in Marketplace (Higgins only)
  • Covers Medicare benefits; Medicare cost sharing applies for those not eligible for subsidies
  • Pays Medicare rates for the buy-in, and providers that participate in Medicare also participate in the buy in
Schatz

S.489, State Public Option Act

  • Allows states to offer a public option based on Medicaid
  • States set premiums and cost sharing, federal matching payments for any losses; no other changes to marketplace subsidies’
  • Pays Medicare rates to primary care providers, Medicaid rate to all others; Medicaid providers and managed care organizations participate in public option
Bennet/ Delgado

S.981 / H.R.2000, Medicare-X Choice Act of 2019

  • Creates a federal public option available to marketplace-eligible individuals
  • Enhances marketplace subsidies for eligible participants
  • Requires Medicare providers to participate in public option; Medicare payment rates used; Secretary may increase payments up to 25% for rural providers
Schakowsky

H.R.2085, CHOICE Act

  • Creates a federal public option available to marketplace-eligible individuals
  • Does not change marketplace subsidies
  • Requires Medicare providers to participate in public option, with opt out; Secretary to negotiate payment rates, with current Medicare rates as default
Merkley

S.1261, Choose Medicare Act

  • Creates a federal public option available to marketplace-eligible individuals and large and small employers
  • Permits large, self-funded employer plans to hire public option as third-party administrator
  • Enhances marketplace subsidies for eligible participants
  • Requires Medicare providers to participate in public option; Secretary establishes public option provider payment rates between Medicare and commercial rates
DeLauro

H.R.2452, Medicare for America Act of 2019

  • Creates a federal public program with comprehensive benefits available to all U.S. residents with allowable opt-out for other qualified coverage
  • Eliminates premiums and cost sharing below 200% of the FPL; income-related premiums and cost sharing to 600% FPL with cap on premium payments of 8% of income
  • Covers essential health benefits, dental, vision, hearing, long-term care, all other current Medicaid-covered benefits
  • Requires Medicare and Medicaid providers to participate in public option; higher of Medicare or Medicaid payment rates used with hospitals paid 110% of applicable rate
  • Replaces marketplaces, Medicaid, individual health insurance, Medicare, and CHIP; employers can continue to offer qualified group plan coverage
NOTES: Candidate proposals are listed by order of introduction within each category. Amy Klobuchar also supports a public option, per her campaign website, but does not outline a specific proposal. Andrew Yang announced his support for giving employees the option to enroll in Medicare-for-all instead of an employer plan. Elizabeth Warren has also introduced a separate proposal for Medicare-for-all; she describes her public option plan as a transition to Medicare-for-all. Congressional proposals are listed by order of introduction within each category. For more detail on congressional bills, see Compare Medicare-for-all and Public Plan Proposals

Endnotes

  1. Under the ACA, individuals with an offer of employer-sponsored coverage can still be eligible for marketplace subsidies if the employer plan fails to meet standards of affordability or minimum value. An employer-sponsored plan is considered affordable if the worker’s premium contribution for self-only coverage does not exceed 9.78% of income. An employer-sponsored plan meets minimum value standards if it has an actuarial value of at least 60%. ↩︎
  2. In the marketplace in 2020, the federal poverty level is $12,490 for an individual and $21,330 for a family of three. ↩︎
  3. The ACA sets a benchmark for covered benefits under marketplace QHPs based on the most popular small group health insurance plan on a state, or based on similar benchmarks that states may choose, such as the largest state public employee health benefit plan. While most plans that are sponsored by larger employers are considered comprehensive, they are not required to cover the essential health benefit package applicable to QHPs. ↩︎
  4. Under the Medicare buy-in proposals, people buying Medicare would be able to use cost sharing reduction subsidies to lower deductibles and add annual-out-of-pocket limits on other cost sharing under traditional Medicare. ↩︎
  5. For additional studies on this topic, see: MedPAC, 2019; White and Whaley, 2019; Beiner and Selden, 2017. ↩︎

Quick Look: Antiretroviral Price Increases in Medicare Part D

Published: Dec 17, 2019

Key Facts

Drug price concerns in the U.S., including for antiretrovirals, the mainstay of HIV treatment and, increasingly prevention, have prompted the introduction of several policy proposals. One proposal would require manufacturers to provide a rebate to Medicare if prices increase faster than inflation. As a drug class, ARVs lack competition in the U.S. market and few generic options are available, leading to particular concerns over their pricing. We assessed list price changes between 2016 and 2017 for ARVs under Medicare Part D, which is required to cover all or substantially all ARVs. During this period, 48 ARVs were covered by Part D, 38 of which were brand medications and 30 were single source.

According to our analysis:

  • Almost three quarters (73% or 35 medications) had list price increases that exceeded the inflation rate between July 2016 and July 2017 (1.7%). This compares to 60% of Part D medications overall. Most of these were brand-name medications (32), and the vast majority were single source (27).
  • Of the 8 ARVs that had price decreases over the period, all were available as generics.
  • ARVs with the highest total Medicare spending and enrollee utilization had price increases exceeding inflation by at least 5 percentage points. All of these were brand name, single source drugs.

These findings suggest that current proposals that seek to control Part D prices relative to inflation could yield savings.

Background

Ongoing concerns about prescription drug pricing and affordability in the United States have prompted the introduction of policy proposals from the White House, members of Congress, and presidential candidates. Some of these proposals would require drug manufacturers to pay a rebate to the federal government if their prices for drugs covered under Medicare Part B and Part D increase by more than the rate of inflation. Indeed, a recent KFF analysis found that list price increases for more than half of Medicare Part D drugs exceeded inflation in 2017, in some cases by a substantial margin, suggesting opportunities for significant savings under these plans.

We used the same methodology to assess price changes for antiretroviral medications (ARVs) under Part D, which is required to cover all or substantially all ARVs as one of six protected drug classes. ARVs are the mainstay of HIV treatment and, increasingly prevention. National treatment guidelines recommend initiating ARV treatment upon an HIV diagnosis; for those at high risk, pre-exposure prophylaxis, or PrEP, with ARVs is recommended to prevent HIV acquisition.

While only a small share of people in the U.S. have HIV or are on PrEP, spending on ARVs has an outsized impact on prescription drug spending across payers. In addition, concerns have been raised about ARV drug pricing and affordability specifically, where list prices for a typical recommended HIV treatment regimen could range from $22,000 to $38,000 per year. High prices are, in part, driven by the lack of manufacturer competition and minimal availability of generic substitutes within the U.S. ARV market, the very types of drugs targeted by several of the prescription drug policy proposals.

To assess changes in the list prices of ARVs covered by Medicare Part D relative to inflation, we used data from the CMS Medicare Part D Spending Dashboard to identify ARVs used in the two most recent years available (2016 and 2017). List price changes were measured by one-year (2016-2017) changes in average spending per dosage unit amounts reported. Our analysis is based on unit prices that do not reflect manufacturer rebates and discounts to plans, which are considered proprietary and therefore not publicly available (the major proposals being considered are not based on post-rebate prices). Inflation was measured over the same period using the Consumer Price Index for all urban consumers (CPI-U), which was 1.7% between 2016 and 2017. A full methodology can be found here.

Findings

The 2019 Medicare Part D Spending Dashboard includes 48 antiretrovirals that were utilized in 2016 and 2017, including both brand and generic drugs (see Table 1). Most ARVs (38 or 79%) were brand medications and almost two-thirds (30 or 63%) were single source, meaning they had no generic alternative (see Figure 1).

Figure 1; Most Antiretrovirals Covered by Medicare Part D (as of 2017) Are Brand-Name, Single Source Medications

Of the 48 ARVs reported in the 2017 Part D dashboard, almost three-quarters (35 drugs or 73%) had list price increases that exceeded inflation between July 2016 and July 2017 (1.7%). This compares to 60% of Part D medications overall. Most of these price increases were more than 3 times the rate of inflation. Almost all drugs with price increases exceeding inflation were brand-name medications (32), and the vast majority were single source (27). Of the remaining ARVs, 10% (or 5 drugs) had list price increases below inflation between 2016 and 2017, and 17% (8 drugs) had price decreases over this period. All 8 of the ARVs with price decreases were available as generics (see Figure 2).

Figure 2: Almost Three-Quarters of Antiretrovirals Covered by Medicare Part D Had List Price Increases Above Inflation Between 2016 and 2017

We examined price increases for ARVs with the highest spending and utilization among Part D enrollees. Among the 10 ARVs with the highest Part D spending in 2017, all were brand-name, single source medications, and all had list price increases exceeding inflation by at least 5 percentage points (see Figure 3). For instance, Genvoya, the ARV with the highest Part D spending, had a price increase of 7.4%. Triumeq, the ARV with the second highest spending, had a price increase of 9.6%, nearly six times the rate of inflation. Truvada, used for HIV treatment as well as PrEP, had the fourth highest Part D spending, and a list price increase of 7.5%. Until 2019, Truvada was the only ARV approved for PrEP.

Figure 3: Among the 10 Antiretrovirals with the Highest Part D Spending in 2017, All Had List Price Increases Exceeding Inflation

Among the top 10 most commonly used ARVs, 9 had list price increases exceeding inflation by at least 5 percentage points and, as with spending, all were brand-name, single source drugs (see Figure 4). The top two most commonly used ARVs – Tivicay and Truvada, each with over 36,000 users in 2017 – had list prices that increased by 9.6% and 7.5%, respectively.

Figure 4: Among the Most Commonly Used Antiretrovirals Covered by Part D in 2017, 9 of 10 Had List Prices Exceeding Inflation

Conclusion

As with Medicare Part D drugs overall, the majority of ARVs had price increases that exceeded the rate of inflation by several percentage points. Moreover, reflecting the lack of competition within the U.S. ARV market, most of these were brand-name, single source medications, including those with the highest spending and greatest utilization, the very types of medications targeted by current policy proposals. These findings suggest that such proposals could yield savings for public and private payers and for patients. However, proposals that place limits on year-to-year drug price increases may incentivize manufactures to introduce newer medications at higher prices. This could present particular challenges in the case of HIV, where several newer treatment and prevention regimens are on the near-term horizon.

Table 1: List Price Changes Between 2016-2017 for ARVs by Total Medicare Part D Spending in 2017
Drug NameTotal Part D Spending in 2017Number of Users in 20172016-2017 List Price Change
Genvoya$689,941,011.3428,6327.4%
Triumeq$650,941,450.2227,5619.6%
Tivicay$518,431,674.9336,6119.6%
Truvada$416,800,910.9436,5527.5%
Atripla$415,313,758.6418,1487.3%
Descovy$404,070,231.2731,5337.3%
Prezista$350,738,609.3427,2119.5%
Isentress$320,942,015.5325,6679.2%
Odefsey$228,725,946.8710,6647.2%
Prezcobix$223,824,222.8716,1539.0%
Stribild$171,008,928.087,4118.4%
Viread$166,748,054.5520,4097.7%
Reyataz$145,194,479.4011,6826.6%
Complera$109,054,960.065,2638.3%
Norvir$100,716,172.1935,2120.2%
Intelence$99,729,416.459,10810.2%
Sustiva$57,430,302.286,1957.5%
Selzentry$49,645,406.083,2829.4%
Kaletra$38,421,347.874,7217.1%
Abacavir-Lamivudine$36,163,620.289,471-30.2%
Edurant$33,470,096.303,9579.1%
Evotaz$32,508,946.372,4267.4%
Epzicom$26,139,505.744,150-2.0%
Lexiva$17,792,125.431,5419.1%
Abacavir$16,159,350.368,022-5.8%
Lamivudine$12,136,669.359,734-7.3%
Abacavir-Lamivudine-Zidovudine$10,164,840.099733.2%
Emtriva$9,769,395.382,8280.2%
Lamivudine-Zidovudine$8,943,870.544,035-20.1%
Nevirapine ER$8,783,702.012,042-10.1%
Viracept$7,356,137.427998.9%
Fuzeon$5,917,901.941986.5%
Invirase$3,824,859.013506.6%
Aptivus$2,780,380.011967.8%
Combivir$1,129,748.721652.0%
Nevirapine$956,975.662,5851.4%
Didanosine$885,882.0652210.8%
Ziagen$861,764.65331-6.5%
Trizivir$799,844.30943.6%
Viramune XR$757,400.112127.3%
Zidovudine$562,555.681,857-0.5%
Crixivan$510,444.651450.2%
Epivir$437,552.2046658.3%
Viramune$437,525.85865.4%
Stavudine$310,975.885317.0%
Tybost$182,986.761636.7%
Rescriptor$104,025.14247.3%
Videx EC$8,506.460.6%
NOTE: List price changes are based on average spending per dosage unit and do not account for rebates. – indicates data not available due to small sample size.SOURCE: KFF analysis of CMS Medicare Part D Drug Spending and Utilization Data, 2016-2017.
News Release

Health Policy Resources for Covering the Democratic Presidential Primary Debates

Published: Dec 16, 2019

As the Democratic presidential candidates continue to debate and campaign for their party’s 2020 nomination, health care ranks high on the list of issues that Democrats and Democratic-leaning independents want the candidates to discuss. KFF offers independent, non-partisan policy analysis, polling and other research and has experts who can provide context, explain trade-offs and provide key data points on health care issues that may arise in the debates and broader campaign. Some key resources:

Medicare-for-all and Other Proposals to Expand Public Coverage

  • Our November poll examines which candidates Democrats trust on health care and assesses public support for Medicare-for-all and a public option. This slideshow captures our most relevant polling data on the public’s views of Medicare-for-all, a public option and other approaches.
  • This slideshow highlights the leading candidates’ positions on Medicare-for-all and a public option, including key differences among plans. This side-by-side comparison tool compares the major bills introduced in Congress this year to expand public health coverage. This explainer examines key aspects of public option proposals and their potential implications.
  • This column from KFF’s Drew Altman highlights how Medicare-for-all is popular with Democrats in key battleground states but significantly less so among swing voters. (Additional Drew Altman columns here.)

Affordable Care Act and Protections for Pre-Existing Conditions

  • This explainer examines the potential impact of the Texas v. U.S. court case that, with the Trump Administration’s support, aims to overturn the entire ACA. This chart collection highlights key polling data related to the ACA and its provisions.
  • This updated analysis estimates the number and share of people by state with “declinable” pre-existing conditions that would have prevented them from buying their own health insurance based on the underwriting practices in place in most states prior to the ACA.

Prescription Drug Costs

  • This brief describes recent and proposed changes to control Medicare drug spending and lower beneficiaries’ out-of-pocket costs. This slideshow compares key features of the House-passed bill, the Senate Finance Committee’s bi-partisan bill, and a House Republicans’ bill. This explainer examines the concept of allowing Medicare to negotiate drug prices.
  • Our February poll looks at Americans’ experiences with prescription drugs and their views on policy changes aimed at lowering drug prices. This data note probes seniors’ experiences.

Health Costs and Surprise Medical Bills

  • This analysis estimates how often consumers receive surprise medical bills when getting emergency room and hospital care, and describes key proposals to protect consumers. This brief looks at variations by conditions, with heart attack patients and women undergoing mastectomies having a higher-than-average chance of getting an unexpected out-of-network bill.
  • This polling data note looks at Americans’ challenges affording health care.

Abortion and Other Reproductive Health Issues

  • This January poll dives into the public’s opinion and knowledge about abortion.
  • This analysis looks at state laws affecting insurance coverage for abortion services in Medicaid, Affordable Care Act (ACA) Marketplace plans, and other private insurance. This brief examines the Hyde Amendment, which prohibits federal funds from being used to pay for abortion with limited exceptions.
  • This updated slideshow examine the public’s views on Roe v. Wade, state laws prohibiting abortions after a “fetal heartbeat” is detected, coverage for preventive services under the ACA, new Title X regulations, and other reproductive health policy issues.
  • This updated fact sheet summarizes state and local policies on paid family and sick leave and presents data from the KFF Employer Health Benefits Surveys on the share of firms that offer workers these benefits.

Medicaid and the Uninsured

  • This report assesses the effects of the ACA’s Medicaid expansion on coverage, access to care, state budgets, and the economy in states that adopted it.
  • This brief looks at how the number of people without health insurance changed under the ACA and why millions remain uninsured today. This brief looks at health coverage and care, and he uninsured rate, for undocumented immigrants, who are ineligible for Medicaid, Medicare and ACA coverage.

Climate Change

  • This national survey conducted jointly by KFF and The Washington Post examines the public’s views, awareness, and preferences related to climate change, including support for policy solutions to address climate change and their willingness to accept economic trade-offs associated with policy solutions,

If you have questions about any of these resources or want to talk to a KFF expert, please contact Rakesh SinghCraig Palosky, Chris Lee or Nikki Lanshaw for assistance.